6578 Stock Overview
A specialized biotech company, primarily engages in the development of antibiotics alternatives in animal health industry. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
My Notes
Capture your thoughts, links and company narrative
DaBomb Protein Biotech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.30 |
| 52 Week High | NT$33.90 |
| 52 Week Low | NT$18.00 |
| Beta | 0.64 |
| 1 Month Change | 2.12% |
| 3 Month Change | -12.87% |
| 1 Year Change | -6.08% |
| 3 Year Change | 9.66% |
| 5 Year Change | -11.91% |
| Change since IPO | -39.21% |
Recent News & Updates
Shareholder Returns
| 6578 | TW Personal Products | TW Market | |
|---|---|---|---|
| 7D | -1.3% | -3.3% | 0.9% |
| 1Y | -6.1% | -19.7% | 28.9% |
Return vs Industry: 6578 exceeded the TW Personal Products industry which returned -19.7% over the past year.
Return vs Market: 6578 underperformed the TW Market which returned 28.9% over the past year.
Price Volatility
| 6578 volatility | |
|---|---|
| 6578 Average Weekly Movement | 3.9% |
| Personal Products Industry Average Movement | 4.0% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6578 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6578's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Yu Fen Liu | www.dabombprotein.com |
DaBomb Protein Biotech Corp., a specialized biotech company, primarily engages in the development of antibiotics alternatives in animal health industry. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023.
DaBomb Protein Biotech Corp. Fundamentals Summary
| 6578 fundamental statistics | |
|---|---|
| Market cap | NT$1.33b |
| Earnings (TTM) | NT$7.22m |
| Revenue (TTM) | NT$356.75m |
180.1x
P/E Ratio3.6x
P/S RatioIs 6578 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6578 income statement (TTM) | |
|---|---|
| Revenue | NT$356.75m |
| Cost of Revenue | NT$284.33m |
| Gross Profit | NT$72.42m |
| Other Expenses | NT$65.20m |
| Earnings | NT$7.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 20.30% |
| Net Profit Margin | 2.02% |
| Debt/Equity Ratio | 24.8% |
How did 6578 perform over the long term?
See historical performance and comparisonDividends
2.8%
Current Dividend Yield489%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 08:51 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DaBomb Protein Biotech Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|